
Knowledge is limited on the potential exclusion from pay-for-performance (P4P) programs of patients living with diabetes who have with individual or neighborhood social risks.

Knowledge is limited on the potential exclusion from pay-for-performance (P4P) programs of patients living with diabetes who have with individual or neighborhood social risks.

“As we look over the next decade, the climb is going to be steep, it's going to be challenging, but success is still possible,” said Luke Greenwalt, vice president of market access at IQVIA, during his session at Asembia 2023.

Just 29% of patients listed a treatment-response goal among their top personal goals.

Speakers at the 2023 Asembia Specialty Pharmacy Summit outlined how artificial intelligence (AI) tools for pharmaceuticals, such as parcel tracking, could reduce operational costs for specialty pharmacies and mitigate drug delivery issues for patients.

Findings show these drugs were linked with a lower risk of progression to inflammatory arthritis compared with tumor necrosis factor inhibitors, although more research is needed to confirm the finding.

This form of reinforcement learning was also shown to correct for control scenarios like irregular meal timing and compression errors.

Biotech company EQRx discards low-cost drug plan, cuts its therapy programs to 1, and slashes staff in “reset”; health care systems’ preparation for new Alzheimer disease drug takes location and resources into consideration; the Drug Enforcement Administration (DEA) will extend telemedicine prescribing for certain controlled medications through at least November 11.

Treatment with dupilumab demonstrated improvements in histological markers, symptoms, and endoscopic markers of eosinophilic esophagitis (EoE) regardless of previous history of esophageal dilation.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

The behavioral economic biases of 43 African American young adults aged 18 to 24 were evaluated on 4 fronts: present bias, information salience, overoptimism, and loss aversion.

The results of a new focus group offer insights on how and when people with rare diseases are willing to share their personal health information.

Just over a year since AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular (CV) death and heart failure–related hospitalizations for dapagliflozin (Farxiga) based on results of the phase 3 DELIVER trial.

The task force was motivated by a gap between in breast cancer deaths between Black and White women.

A panel on women’s health disparities at the 2023 Asembia Specialty Pharmacy Summit addressed the current challenges women face regarding health care as well as how digital tools, collaboration between clinics and governments, and more detailed and inclusive research can help improve health equity for all women.

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).

The end of the COVID-19 public health emergency spotlights US outbreak tracking weakness; the American Psychological Association released guidelines to guide teen social media use; the first study funded by the US government to measure safe injection site effectiveness was announced Monday.

The relationship between myopia and primary open-angle glaucoma (POAG) was stronger in Asian, Black, and Hispanic individuals compared with White individuals.

China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.

The prevalence of Clostridioides difficile has risen in recent years, and although its carriage is recognized in infancy, limited data exist on its longitudinal trends.

This longitudinal analysis of claims data examined changes in telehealth and in-person delivery of services in Louisiana.

An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.

In addition to current available risk scores, the new system can help counsel patients with myelofibrosis (MF) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT), authors wrote.

Study authors said the findings could inform clinicians when selecting therapies for patients with type 2 diabetes (T2D). However, an editorial found the follow-up period too short and differences between the study arms too small to be meaningful.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR technology has seen success and potential areas for future application.

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the role the new wave of biosimilars will have on rebate practices for both pharmacy benefit managers (PBMs) and payers.

Treatment options have improved care, but also increased the need for patient education.

A study found that not being infected with respiratory syncytial virus (RSV) in the first year of life was associated with a decreased risk of developing asthma in childhood.

The possible consequences for health care if the United States breaches the debt ceiling; skepticism follows proposal for over-the-counter birth control pill; North Carolina governor calls potential abortion ban harmful.

After winning our Seema S. Sonnad Emerging Leader in Managed Care Research Award, these researchers have gone on to make substantial impacts in the field of managed care and mentor the next generation of investigators.

Cost sharing for several treatments could disappear following the Braidwood v Becerra ruling, according to A. Mark Fendrick, MD, director of the V-BID Center at the University of Michigan and co-editor in chief of The American Journal of Managed Care®.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
